| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ebb6a553affdc364c91cffe3baf12564 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-445
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4468
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-14 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D211-62
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4468
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-445 |
| filingDate |
1996-07-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
1997-05-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9358b1261437c3b4cff92536d5200a94
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5ca36d47a11e747fc370dd1e4126f914 |
| publicationDate |
1997-05-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-5629329-A |
| titleOfInvention |
Methods for treating disorders associated with the central nervous system using opticallly pure (+) cisapride |
| abstract |
Methods are disclosed utilizing the optically pure (+) isomer of cisapride. This compound is a potent drug for the treatment of gastro-esophageal reflux disease while substantially reducing the concomitant liability of adverse effects associated with the racemic mixture of cisapride. This compound is also useful in treating or preventing emesis while substantially reducing adverse effects associated with racemic cisapride. The optically pure (+) isomer of cisapride is also useful for the treatment of dyspepsia and such other conditions as may be related to the activity of (+) cisapride as a prokinetic agent, such as gastroparesis, constipation, post-operative ileus, and intestinal pseudo-obstruction, without the concomitant liability of adverse effects associated with the racemic mixture of cisapride. The (+) isomer of cisapride also exhibits longer duration of action than does racemic cisapride and is useful for treatment of disorders of the central nervous system. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2008085915-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6559165-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7326787-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2005176757-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7064138-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7282509-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2008085921-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7176218-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6596686-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6218542-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2008076927-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2007078265-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8524736-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2009137810-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7629466-B2 |
| priorityDate |
1992-07-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |